Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Integer Holdings Corporation or NovoCure Limited because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Integer Holdings Corporation and NovoCure Limited compare based on key financial metrics to determine which better meets your investment needs.

About Integer Holdings Corporation and NovoCure Limited

Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Costa Rica, Puerto Rico, Ireland, and internationally. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; implanted medical devices, implanted leads, procedure accessories, and external devices; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; orthopedics, minimally invasive surgery, and general surgery devices; and portable medical devices, including patient monitoring, ventilators, portable defibrillators, portable ultrasound, and X-Ray machines. Furthermore, the company provides medical technologies; supplies medical stamped components, and shallow and deep draw casings and assemblies; and epicardial pacing leads. It serves multi-national original equipment manufacturers and affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, cardio and vascular, and advanced surgical and portable medical markets. The company provides its products under the Greatbatch Medical and the Lake Region Medical brands. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Latest Health Care Equipment & Supplies and Integer Holdings Corporation, NovoCure Limited Stock News

As of March 9, 2026, Integer Holdings Corporation had a $2.9 billion market capitalization, compared to the Health Care Equipment & Supplies median of $317.4 million. Integer Holdings Corporation’s stock is NA in 2026, NA in the previous five trading days and down 30.03% in the past year.

Currently, Integer Holdings Corporation’s price-earnings ratio is 29.5. Integer Holdings Corporation’s trailing 12-month revenue is $1.9 billion with a 5.5% net profit margin. As of March 9, 2026, Integer Holdings Corporation has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $6.476 per share for the current fiscal year. Integer Holdings Corporation does not currently pay a dividend.

Currently, NovoCure Limited does not have a price-earnings ratio. NovoCure Limited’s trailing 12-month revenue is $655.4 million with a -20.8% net profit margin. Year-over-year quarterly sales growth most recently was 8.1%. Analysts expect adjusted earnings to reach $-1.510 per share for the current fiscal year. NovoCure Limited does not currently pay a dividend.

How We Compare Integer Holdings Corporation and NovoCure Limited Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Integer Holdings Corporation and NovoCure Limited’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Integer Holdings Corporation and NovoCure Limited Growth Grades

Company	Ticker	Growth
Integer Holdings Corporation	ITGR	A
NovoCure Limited	NVCR	C

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Integer Holdings Corporation has a Growth Score of 89, which is Very Strong. NovoCure Limited has a Growth Score of 50, which is Average.

The Growth Grade Winner: Integer Holdings Corporation

As you can clearly see from the Growth Grade breakdown above, Integer Holdings Corporation has a more attractive growth grade than NovoCure Limited. For investors who focus solely on how a company is growing relative to other companies in the same industry, Integer Holdings Corporation could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Integer Holdings Corporation and NovoCure Limited’s Quality Grades

Company	Ticker	Quality
Integer Holdings Corporation	ITGR	C
NovoCure Limited	NVCR	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Integer Holdings Corporation has a Quality Score of 49, which is Average. NovoCure Limited has a Quality Score of 63, which is Strong.

The Quality Grade Winner: NovoCure Limited

As you can clearly see from the Quality Grade breakdown above, NovoCure Limited has a better overall quality grade than Integer Holdings Corporation. For investors who are looking for companies with higher quality than others in the same industry, NovoCure Limited could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Integer Holdings Corporation and NovoCure Limited’s Momentum Grades

Company	Ticker	Momentum
Integer Holdings Corporation	ITGR	C
NovoCure Limited	NVCR	D

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Integer Holdings Corporation has a Momentum Score of 41, which is Average. NovoCure Limited has a Momentum Score of 24, which is Weak.

The Momentum Stock Winner: No Clear Winner

Neither Integer Holdings Corporation or NovoCure Limited has a strong enough Momentum Grade to be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Integer Holdings Corporation or NovoCure Limited is the better investment when it comes to momentum.

Other Integer Holdings Corporation and NovoCure Limited Grades

In addition to Growth, Momentum and Quality, A+ Investor also provides grades for Value and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Integer Holdings Corporation and NovoCure Limited pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Integer Holdings Corporation or NovoCure Limited Stock?

Overall, Integer Holdings Corporation stock has a Growth Score of 89, Momentum Score of 41 and Quality Score of 49.

NovoCure Limited stock has a Growth Score of 50, Momentum Score of 24 and Quality Score of 63.

Comparing Integer Holdings Corporation and NovoCure Limited’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.